Staar Surgical downgraded to Hold from Buy at Canaccord

Canaccord analyst William Plovanic downgraded Staar Surgical to Hold from Buy with a price target of $48, down from $77. The company posted an in-line Q2 but investors will focus on the forward guidance, which Staar pulled down significantly, the analyst tells investors in a research note. The firm says company is seeing challenges in its U.S. adoption, and that economic headwinds in both South Korea and Europe will likely persist through the rest of the year.